Trial Profile
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2016
Price :
$35
*
At a glance
- Drugs Seribantumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Merrimack Pharmaceuticals
- 03 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Mar 2013 Planned End Date changed from 1 Sep 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.